Loading organizations...
Loading organizations...
Ostro develops a platform designed to foster meaningful connections between life sciences companies and individuals seeking medical treatments. The company’s core product empowers both consumers and healthcare providers with control over when and how they receive health information, enabling informed decision-making regarding available medicines, treatments, and diagnostics. Its technical approach centers on streamlining access to crucial health data, thereby bridging the gap between developers of medical solutions and their end-users.
Founded in 2019 by Chase Feiger, MD, Ahmed Elsayyad, and Ryan Junee, Ostro emerged from a shared recognition that people faced significant challenges in identifying and accessing appropriate medical care. The founders, leveraging their diverse backgrounds in venture capital, healthcare, and rapidly scaling technology ventures, perceived an opportunity to innovate within the life sciences sector. Their initial insight focused on simplifying the patient journey and enhancing information flow.
Ostro serves life sciences organizations by facilitating direct and impactful engagement with their target audiences, including both patients and healthcare professionals. The company’s overarching mission is to improve global health outcomes by serving as a crucial link within the healthcare ecosystem. It aims to ensure that millions of people can lead healthier lives through better access to necessary medical information and appropriate therapeutic options.
Ostro has raised $45.0M across 1 funding round.
Ostro has raised $45.0M in total across 1 funding round.
Ostro has raised $45.0M in total across 1 funding round.
Ostro's investors include 1776, Acrew Capital, cofounder, Fifth Wall, Greycroft, Moonshots Capital, SoftBank Investment Advisers, Howard Schultz, Jeffrey Wilke, Kathleen Hale, Russell Cook.
Ostro is a healthcare technology company founded in 2019 that builds an AI-powered digital engagement platform for life sciences brands, connecting pharmaceutical, medical device, and diagnostic companies with consumers, caregivers, and healthcare providers (HCPs).[1][2][3] Its products, including Ostro Navigate, Prompt, Airmark, Tailor, and Consult, create personalized, compliant journeys that optimize diagnosis, treatment access, and engagement, serving therapeutic areas like oncology, rare disease, and cardiology.[2][3] Ostro solves the problem of fragmented information in healthcare by empowering users to find the right treatments faster, with metrics showing 4x higher completion of high-value actions, 30% increased click-through rates, and impact on over 10 million people.[3] The company demonstrates strong growth momentum as a private firm with pre-IPO interest, a team from Google, Amazon, and McKinsey, and recognition as a top workplace in 2025.[4][6]
Ostro was founded in 2019 by Chase Feiger, MD, Ahmed Elsayyad, and Ryan Junee, who brought expertise from venture capital, healthcare, and high-growth tech to disrupt life sciences.[1][4] The idea emerged from a passion to empower consumers and HCPs with control over health information and actionable insights, addressing gaps in treatment access.[1] Originally known as RxDefine, the company rebranded to Ostro to better communicate its mission of navigating complex healthcare systems, with early traction built on an end-to-end AI commercialization platform.[5][2] Pivotal moments include scaling to serve mid-sized biotechs and achieving widespread adoption, evidenced by its role in helping 10M+ users and partnerships across therapeutic areas.[3]
Ostro rides the wave of AI-driven personalization in healthcare, capitalizing on demand for seamless digital experiences amid rising consumer expectations and complex treatment landscapes.[3][2] Timing is ideal with life sciences shifting to patient-centric models, fueled by regulatory pushes for compliant engagement and post-pandemic telehealth growth.[3] Market forces like expanding biotech innovation and therapeutic advancements in oncology and rare diseases favor Ostro's scalable platform, which bridges pharma brands with fragmented audiences.[2] It influences the ecosystem by setting standards for empathetic AI tools, partnering with emerging biotechs to accelerate commercialization, and boosting outcomes for millions, akin to peers like Ro or Benchling in health tech.[3][4]
Ostro is poised for accelerated expansion through deeper AI integrations and biotech partnerships, potentially eyeing IPO as pre-IPO trading heats up.[4] Trends like multimodal AI, regulatory evolution for digital health, and personalized medicine will propel its growth, amplifying influence in life sciences commercialization.[2][3] As it scales from 10M+ users, Ostro could redefine empathetic engagement, evolving from a connector to a core infrastructure player—empowering healthier lives at the intersection of tech and medicine, true to its founding passion.[1]
Ostro has raised $45.0M across 1 funding round. Most recently, it raised $45.0M Series B in April 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2022 | $45.0M Series B | 1776, Acrew Capital, cofounder, Fifth Wall, Greycroft, Moonshots Capital, SoftBank Investment Advisers, Howard Schultz, Jeffrey Wilke, Kathleen Hale, Russell Cook |
